Cargando…

COVID-19 antibody seroprevalence in Santa Clara County, California

BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendavid, Eran, Mulaney, Bianca, Sood, Neeraj, Shah, Soleil, Bromley-Dulfano, Rebecca, Lai, Cara, Weissberg, Zoe, Saavedra-Walker, Rodrigo, Tedrow, Jim, Bogan, Andrew, Kupiec, Thomas, Eichner, Daniel, Gupta, Ribhav, Ioannidis, John P A, Bhattacharya, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928865/
https://www.ncbi.nlm.nih.gov/pubmed/33615345
http://dx.doi.org/10.1093/ije/dyab010
_version_ 1783659900057944064
author Bendavid, Eran
Mulaney, Bianca
Sood, Neeraj
Shah, Soleil
Bromley-Dulfano, Rebecca
Lai, Cara
Weissberg, Zoe
Saavedra-Walker, Rodrigo
Tedrow, Jim
Bogan, Andrew
Kupiec, Thomas
Eichner, Daniel
Gupta, Ribhav
Ioannidis, John P A
Bhattacharya, Jay
author_facet Bendavid, Eran
Mulaney, Bianca
Sood, Neeraj
Shah, Soleil
Bromley-Dulfano, Rebecca
Lai, Cara
Weissberg, Zoe
Saavedra-Walker, Rodrigo
Tedrow, Jim
Bogan, Andrew
Kupiec, Thomas
Eichner, Daniel
Gupta, Ribhav
Ioannidis, John P A
Bhattacharya, Jay
author_sort Bendavid, Eran
collection PubMed
description BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara County. METHODS: On 3 and 4 April 2020, we tested 3328 county residents for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to SARS-CoV-2 using a rapid lateral-flow assay (Premier Biotech). Participants were recruited using advertisements that were targeted to reach county residents that matched the county population by gender, race/ethnicity and zip code of residence. We estimate weights to match our sample to the county by zip, age, sex and race/ethnicity. We report the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We adjust for test-performance characteristics by combining data from 18 independent test-kit assessments: 14 for specificity and 4 for sensitivity. RESULTS: The raw prevalence of antibodies in our sample was 1.5% [exact binomial 95% confidence interval (CI) 1.1–2.0%]. Test-performance specificity in our data was 99.5% (95% CI 99.2–99.7%) and sensitivity was 82.8% (95% CI 76.0–88.4%). The unweighted prevalence adjusted for test-performance characteristics was 1.2% (95% CI 0.7–1.8%). After weighting for population demographics, the prevalence was 2.8% (95% CI 1.3–4.2%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 53 000 [95% CI 26 000 to 82 000 using weighted prevalence; 23 000 (95% CI 14 000–35 000) using unweighted prevalence] people were infected in Santa Clara County by late March—many more than the ∼1200 confirmed cases at the time. CONCLUSION: The estimated prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that COVID-19 was likely more widespread than indicated by the number of cases in late March, 2020. At the time, low-burden contexts such as Santa Clara County were far from herd-immunity thresholds.
format Online
Article
Text
id pubmed-7928865
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79288652021-03-04 COVID-19 antibody seroprevalence in Santa Clara County, California Bendavid, Eran Mulaney, Bianca Sood, Neeraj Shah, Soleil Bromley-Dulfano, Rebecca Lai, Cara Weissberg, Zoe Saavedra-Walker, Rodrigo Tedrow, Jim Bogan, Andrew Kupiec, Thomas Eichner, Daniel Gupta, Ribhav Ioannidis, John P A Bhattacharya, Jay Int J Epidemiol Covid-19 BACKGROUND: Measuring the seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is central to understanding infection risk and fatality rates. We studied Coronavirus Disease 2019 (COVID-19)-antibody seroprevalence in a community sample drawn from Santa Clara County. METHODS: On 3 and 4 April 2020, we tested 3328 county residents for immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to SARS-CoV-2 using a rapid lateral-flow assay (Premier Biotech). Participants were recruited using advertisements that were targeted to reach county residents that matched the county population by gender, race/ethnicity and zip code of residence. We estimate weights to match our sample to the county by zip, age, sex and race/ethnicity. We report the weighted and unweighted prevalence of antibodies to SARS-CoV-2. We adjust for test-performance characteristics by combining data from 18 independent test-kit assessments: 14 for specificity and 4 for sensitivity. RESULTS: The raw prevalence of antibodies in our sample was 1.5% [exact binomial 95% confidence interval (CI) 1.1–2.0%]. Test-performance specificity in our data was 99.5% (95% CI 99.2–99.7%) and sensitivity was 82.8% (95% CI 76.0–88.4%). The unweighted prevalence adjusted for test-performance characteristics was 1.2% (95% CI 0.7–1.8%). After weighting for population demographics, the prevalence was 2.8% (95% CI 1.3–4.2%), using bootstrap to estimate confidence bounds. These prevalence point estimates imply that 53 000 [95% CI 26 000 to 82 000 using weighted prevalence; 23 000 (95% CI 14 000–35 000) using unweighted prevalence] people were infected in Santa Clara County by late March—many more than the ∼1200 confirmed cases at the time. CONCLUSION: The estimated prevalence of SARS-CoV-2 antibodies in Santa Clara County implies that COVID-19 was likely more widespread than indicated by the number of cases in late March, 2020. At the time, low-burden contexts such as Santa Clara County were far from herd-immunity thresholds. Oxford University Press 2021-02-22 /pmc/articles/PMC7928865/ /pubmed/33615345 http://dx.doi.org/10.1093/ije/dyab010 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Covid-19
Bendavid, Eran
Mulaney, Bianca
Sood, Neeraj
Shah, Soleil
Bromley-Dulfano, Rebecca
Lai, Cara
Weissberg, Zoe
Saavedra-Walker, Rodrigo
Tedrow, Jim
Bogan, Andrew
Kupiec, Thomas
Eichner, Daniel
Gupta, Ribhav
Ioannidis, John P A
Bhattacharya, Jay
COVID-19 antibody seroprevalence in Santa Clara County, California
title COVID-19 antibody seroprevalence in Santa Clara County, California
title_full COVID-19 antibody seroprevalence in Santa Clara County, California
title_fullStr COVID-19 antibody seroprevalence in Santa Clara County, California
title_full_unstemmed COVID-19 antibody seroprevalence in Santa Clara County, California
title_short COVID-19 antibody seroprevalence in Santa Clara County, California
title_sort covid-19 antibody seroprevalence in santa clara county, california
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928865/
https://www.ncbi.nlm.nih.gov/pubmed/33615345
http://dx.doi.org/10.1093/ije/dyab010
work_keys_str_mv AT bendavideran covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT mulaneybianca covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT soodneeraj covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT shahsoleil covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT bromleydulfanorebecca covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT laicara covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT weissbergzoe covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT saavedrawalkerrodrigo covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT tedrowjim covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT boganandrew covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT kupiecthomas covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT eichnerdaniel covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT guptaribhav covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT ioannidisjohnpa covid19antibodyseroprevalenceinsantaclaracountycalifornia
AT bhattacharyajay covid19antibodyseroprevalenceinsantaclaracountycalifornia